FDA approves Lytenava for wet AMD

◆ ◆ The Wire takeaway

For 20 years, retina specialists have been injecting a cancer drug into the eye because no ophthalmic version existed. Lytenava closes that gap with 12 years of exclusivity, which means compounders, rival anti-VEGF makers, and anyone selling adjacent diagnostics or delivery devices just lost a large pool of off-label custom. If you're in retinal imaging, injection systems, or patient monitoring in AMD, your customer base now has a purpose-built alternative.